Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy - Observational Long-term Outcome Follow up
Recruiting now
Conditions studied: Severe Sepsis
In brief
Subjects previously enrolled / randomized in the ReActIF-ICE (Recovery from acute immune failure in septic shock by immune cell extracorporeal terapy - immune competence enhancement) study received either standard sepsis treatment (control group) or standard sepsis treatment and additionally the ARTICE treatment (treatment group) during their index hospitalization. All subjects are followed up for 90 days after enrollment. In this long term follow up study, the enrolled subjects shall be followed up beyond 90 days for up to 5 years.
Key facts
- Study ID
- NCT06143137
- Run by
- Artcline GmbH
- People needed
- 142
- Starts
- 2024-01-01
- Expected to finish
- 2030-02-28
- Last updated by the study team
- 2024-08-02
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject or legal surrogate is willing and able to provide written informed consent and comply with all protocol requirements or the implementation of other established procedures according to the local regulations of the contributing center to include subjects who are unable to provide informed consent.
- Subject was enrolled in the ReActIF-ICE study and successfully passed the Day 2 re-evaluation of that trial.
You may not qualify if…
- none
Where it is running
- Klinikum Magdeburg, Klinik für Intensiv- und Rettungsmedizin — Magdeburg, Germany (enrolling)
- Universitätsmedizin Rostock, Abteilung KAI — Rostock, Germany (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.